Shilpa Medicare Limited — PPTs, 10-02-2025: Investor Presentation

Shilpa Medicare reported a solid performance for the quarter ending December 2024, with total revenues of INR 320 crore, marking an 11% year-on-year increase. This growth was primarily driven by the exceptional performances in formulations and biologics. Gross profit improved to INR 229 crore, leading to a gross margin of 72%, and EBITDA increased to INR 82 crore, reflecting a 20% rise. The net profit surged to INR 32 crore, an impressive 588% increase compared to the previous year.

For the nine-month period, revenues reached INR 971 crore, up 12% year-on-year, with EBITDA standing at INR 256 crore and a remarkable PAT of INR 64 crore, nearly doubling from the previous year. Growth strategies include expanding its API portfolio, launching new products, and enhancing regulatory filings, contributing to a positive outlook for sustained revenue growth. The management emphasized ongoing developments in clinical trials and new product launches across its core segments, which are expected to enhance growth potential significantly in the upcoming quarters.